What's driving the Protein Assays Market Growth? Thermo Fisher Scientific Inc., GE Healthcare, Merck KGaA, Bio-Rad Laboratories, Inc., Lonza, Abcam plc, PerkinElmer Inc., Bio-Techne, BioVision Inc., Cell Signaling Technology, Inc., and Geno Technology Inc

Various new biomarker identification systems and emerging new uses for protein assays provided opportunities to the players in the global protein assay market. For instance, in June 2017, Gyros Protein Technologies AB launched a new version of its anti-drug antibody (ADA) solution for the immunogenicity segment. Gyrolab ADA solution enables to automatically run drug-tolerant ADA assays in a time efficient way reducing hands-on time, using small volumes of patient samples and reagents, and reducing run-times.

Free Request Sample Copy of this Report: https://www.coherentmarketinsights.com/insight/request-sample/1087

Manufacturers are likely to focus on launching systems, which are expected to help understand protein structures and functions, with tools to characterize post-translational modifications, localization, and expression control including epigenetic mechanisms. In June 2015, Thermo Fisher Scientific Inc. introduced Orbitrap Fusion Lumos Tribrid mass spectrometer and in 2017, it launched Integrated Ultraviolet Photo separation (UVPD) that enables specialists to perform substantial and little atom structure assurance on a Lorentz focus (LC) time scale; and new advanced peak determination (APD) calculation that is intended to enhance execution of most proteomic work processes with high peptide and protein ID rates.

Protein quantification is a process in protein extraction in biochemistry and molecular biology labs that involves protein extraction, analysis, or labeling. Quantification of protein is required for protein sample and analysis by electrophoresis or chromatography or any other immunochemical techniques. Commonly used protein assays are Bradford, Lowry, BCA, and UV spectroscopic protein assays. In April 2017, Millipore Sigma launched a new Single Molecule Counting Platform, SMCxPROTM, which is based on the principle of immunoassay and it enables precise and sensitive detection over conventional methods.

Get PDF Brochure of Research Report: https://www.coherentmarketinsights.com/insight/request-pdf/1087

Increasing investments of pharmaceutical companies in protein assays is leading to development of various drugs. Protein assays initiatives have led to new discoveries and development of treatments tailored for specific characteristics such as genetic makeup or genetic profile of an individual tumor that helps to offer relatively better and effective treatment methods.

In 2015, According to a publication by Pharmaceuticals Research and Manufacturers of America (PhRMA) — a trade group representing companies in the pharmaceutical industry in the U.S.— the member organizations (pharmaceutical companies) of PhRMA invested around US$ 58.8 billion on R&D, accounting for the largest of all the biopharmaceutical R&D spending in the U.S, in 2015.

Key companies in the protein assay market include Thermo Fisher Scientific Inc., GE Healthcare, Merck KGaA, Bio-Rad Laboratories, Inc., Lonza, Abcam plc, PerkinElmer Inc., Bio-Techne, BioVision Inc., Cell Signaling Technology, Inc., and Geno Technology Inc.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

About Us:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity

This release was published on openPR.